Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: Two-Year Follow-up from a Phase 3 Study

被引：0
|
作者：
Orbai, Ana-Maria [1 ]
Gellett, Amanda M. [2 ]
Kerr, Lisa [2 ]
Constantin, Arnaud [3 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] Hop Pierre Paul Riquet, Toulouse, France
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2559
引用
收藏
页数：3
相关论文
共 50 条
  • [21] IXEKIZUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR-INHIBITORS
    Kavanaugh, A.
    Vender, R.
    Birt, J.
    Adams, D. H.
    Benichou, O.
    Lin, C. -Y.
    Nash, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 941 - 941
  • [22] IXEKIZUMAB REDUCES DISEASE ACTIVITY IN ACTIVE PSORIATIC ARTHRITIS PATIENTS WHO HAD PREVIOUS INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR-INHIBITORS
    Coates, L. C.
    Mease, P.
    Husni, M. E.
    Lespessailles, E.
    Adams, D. H.
    Benichou, O.
    Kerr, L.
    Helliwell, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 679 - 679
  • [23] Ixekizumab Demonstrates Consistent Improvement up to Week 108 in Psoriatic Arthritis Across Individual ACR Components for Patients Naive to Biologic DMARDs or with Previous Inadequate Response to TNF Inhibitors
    Turkiewicz, Anthony
    Sprabery, Aubrey Trevelin
    Gellett, Amanda
    Park, So Young
    Constantin, Arnaud
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [24] Fifty two-week efficacy and safety results from SPIRIT-P1: a Phase 3 study of ixekizumab in patients with active psoriatic arthritis
    Mease, P.
    Okada, M.
    Kishimoto, M.
    Shuler, C.
    Carlier, H.
    Lin, C. -Y.
    Mou, J.
    Moriarty, S.
    Lee, C.
    Gladman, D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 32 - 33
  • [25] Fifty two-week efficacy and safety results from SPIRIT-P1: A Phase 3 study of ixekizumab in patients with active psoriatic arthritis
    Mease, P.
    Okada, M.
    Kishimoto, M.
    Shuler, C.
    Carlier, H.
    Lin, C.
    Mou, J.
    Moriarty, S. R.
    Lee, C.
    Gladman, D.
    Satler, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S260 - S260
  • [26] IXEKIZUMAB MAKES REMISSION AND LOW DISEASE ACTIVITY POSSIBLE IN PATIENTS WITH PSORIATIC ARTHRITIS: TWO-YEAR RESULTS IN TNF INADEQUATE RESPONDERS OR BIOLOGIC-NAIVE PATIENTS
    Coates, Laura C.
    Ogdie, Alexis
    Sunkureddi, Prashanth
    Kerr, Lisa
    Hufford, Matthew
    Helliwell, Philip
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 902 - 903
  • [27] Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from the phase 3 BE COMPLETE study and its open-label extension up to 1 year
    Coates, L.
    Landewe, R. B. M.
    McInnes, I.
    Mease, P. J.
    Ritchlin, C. T.
    Tanaka, Y.
    Asahina, A.
    Behrens, F.
    Gladman, D. D.
    Gossec, L.
    Gottlieb, A. B.
    Warren, R. B.
    Ink, B.
    Bajracharya, R.
    Coarse, J.
    Giger, S.
    Merola, J. F.
    SWISS MEDICAL WEEKLY, 2023, 153 : 24S - 25S
  • [28] SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR
    Coates, L.
    Landewe, R. B. M.
    Mcinnes, I.
    Mease, P. J.
    Ritchlin, C. T.
    Tanaka, Y.
    Asahina, A.
    Behrens, F.
    Gladman, D. D.
    Gossec, L.
    Gottlieb, A. B.
    Warren, R. B.
    Ink, B.
    Bajracharya, R.
    Coarse, J.
    Merola, J. F.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 346 - 347
  • [29] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52 WEEK RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)
    Mease, P. J.
    Okada, M.
    Kishimoto, M.
    Shuler, C. L.
    Carlier, H.
    Lin, C. -Y.
    Mou, J.
    Moriarty, S. R.
    Lee, C. H.
    Gladman, D. D.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 96 - 96
  • [30] SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGICS: 3-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 2 STUDY
    Mease, P. J.
    Setty, A.
    Papp, K.
    Van den Bosch, F.
    Tsuji, S.
    Keiserman, M.
    Carter, K.
    Mccaskill, R.
    Mcdearmon-Blondell, E.
    Wung, P.
    Tillett, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1136 - 1137
12345